“Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation”, Mediterr J Hematol Infect Dis, vol. 11, no. 1, p. e2019057, Aug. 2019, doi: 10.4084/mjhid.2019.057.